$MOLN

Molecular Partners AG (MOLN) reported Q3 2026 results, highlighting progress in its MP0712 Phase 1/2a study for SCLC. The company is focusing on radiopharmaceuticals, streamlining operations, and expects cash to last into late 2027. Initial safety data for MP0712 will be presented in December 2026, with efficacy data expected in 2027. The company also announced potential workforce reductions.

Molecular Partners AG (MOLN) selected MP0730 as its lead Radio-DARPin candidate targeting CD70, a clinically validated antigen in kidney cancer and other indications. Preclinical data in mice showed strong tumor uptake with minimal healthy tissue accumulation. The company plans to start a first-in-human program in mid-2027.

MOLECULAR PARTNERS AG (MOLN) furnished an SEC Form 6-K — earnings release. PRESS RELEASE Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study • DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level

Molecular Partners (SIX, NASDAQ: MOLN) reported H1 2026 results, highlighting progress in its Phase 1/2a trial for MP0712, a DLL3-targeting Radio-DARPin, which has advanced to higher dose levels. The company has CHF 67.9M in cash, expected to fund operations into late 2027. Initial data for MP0712 is anticipated in 2026, with efficacy data in 2027. CD70 was selected as a new target for kidney cancer treatment, with clinical programs starting in 2027.

Molecular Partners AG (MOLN) said its Phase 2 TACTIC trial is ongoing in France to test MP0317 plus durvalumab and gemcitabine-cisplatin versus SoC alone in advanced cholangiocarcinoma. The study plans 75 patients, with 9 sites active. Data are expected in 2027 and completion in 2028. MOLN shares closed at $3.91.

Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) said it has dosed first patients in its Phase 2 TACTIC trial of MP0317 plus durvalumab and gemcitabine-cisplatin for advanced cholangiocarcinoma. The randomized study targets 75 patients, with nine sites recruiting. Data are expected in 2027 and completion in 2028; an ESMO 2026 poster is planned.

Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) presented Radio-DARPin approaches at the Gordon Research Conference on radionuclide theranostics, focusing on multispecific designs to address tumor heterogeneity. The company said lead candidates include MP0712 (DLL3) in a multicenter US Phase 1/2a trial and MP0726 (mesothelin) aiming for first human imaging in 2026.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) updated its targeted alpha Radio-DARPin pipeline. Phase 1/2a dosing is ongoing for MP0712 (DLL3; 212Pb) in a US multicenter study with initial data expected in coming months and fuller safety/efficacy in 2027. FIH imaging for MP0726 (MSLN; planned) starts H2 2026; two INDs and a new target nomination are planned for 2027/2H 2026.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) and Orano Med said first patients were dosed in a US Phase 1/2a trial of DLL3-targeting 212Pb Radio-DARPin MP0712. Five US sites are recruiting; dosing is ongoing in cohort 1 with repeat dosing. Initial data are expected in 2026 and fuller safety/efficacy in 2027 (NCT07278479).

Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells